Leiden, The Netherlands, August 29, 2001 - Crucell N.V. (NASDAQ: CRXL; Euronext Amsterdam: CRXL), today announced that it has appointed Arsia Amir-Aslani as Vice President Corporate Development & Strategy. Dr Amir-Aslani will be responsible for Crucell's investor relations and corporate marketing activities.

Dr Amir-Aslani is a former investment banker and was a senior marketing and communications executive at a specialized healthcare consultancy firm, where he provided distinctive and innovative service to an array of leading US and European biotech companies. Prior to joining Crucell Dr Amir-Aslani was heading the life science practice at the corporate finance department of Oddo Pinatton, a leading French investment banking group, where he concentrated on M&A and business development activities. He is a regular contributor to several scientific and financial magazines. Dr Amir-Aslani holds a Ph.D. in Molecular and Structural Pharmacology from the University of Paris, Pierre et Marie-Curie as well as a Masters' degree in International Management from the University of Paris, Sorbonne.
"Dr Amir-Aslani's in-depth knowledge and experience of the biotechnology sector will be a major asset in communicating Crucell's strategic framework and initiatives to our existing shareholders and potential investors." said Dinko Valerio, CEO of Crucell.

Furthermore, the company also announces that Majid Mehtali has resigned as Vice President Research in order to progress his career outside of Crucell.

"I would like to thank Dr Mehtali for his substantial contribution to the company's success," said Ton Logtenberg, CSO of Crucell. "Crucell has grown tremendously over the past year and Dr Mehtali was instrumental in implementing the adequate infrastructure necessary for securing our future growth."

About Crucell
Crucell, a leading biotechnology company, discovers and develops biopharmaceutical products that utilize the immune system to combat disease. Crucell's human technology platforms, MAbstractTM and PER.C6(TM), are applicable for discovery and development of antibody and vaccine products.
Crucell's MAbstract(TM) discovery and development programs are focused on human antibody-based therapeutics for treatment of cancer and inflammatory diseases. Crucell's vaccine programs are focused on the prevention and treatment of influenza and other infectious diseases. Crucell enters into licensing or co-development agreements for its in-house products, or starts new target discovery and product development programs with partners.
Currently, Crucell has five fully human antibodies in various stages of pre-clinical development for the treatment of colon cancer, breast cancer, anti-angiogenesis, leukemia and inflammation. Additional programs have been launched in oncology, diabetes and cardiovascular diseases. In August 2001, the company entered into an agreement with Centocor, Inc., for the development and commercialization of its CD46-specific human antibodies for the treatment of cancer.
Crucell's PER.C6(TM) fully human production cell line technologies are made available under license agreements for antibodies, proteins, vaccines and vector technology applications. Crucell has currently signed 18 PER.C6(TM) agreements with major pharmaceutical and biotechnology companies.
Crucell has a listing on NASDAQ and Euronext, and has raised EUR 144 million in its October 2000 IPO. Crucell currently employs approximately 130 people in its facilities in Leiden and Utrecht.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. See our Registration Statement, as filed on Form F-1 with the U.S. Securities and Exchange Commission on October 26, 2000, (the "Registration Statement") and the section of the Registration Statement entitled "Risk Factors".

Appointment